Physician profile
Matthew Enzweiler
NPI 1023017522
$1,737.09
in general payments reported to CMS, 2019-2025
37 companies · $183 in 2025
The $183 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $340 · 2020: $95.48 · 2021: $308 · 2022: $251 · 2023: $167 · 2024: $392 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $742.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $218.20 | 2019-2025 | Collagenase Santyl, Grafix Pl, Oasis |
| Stryker Corporation | $183.55 | 2019-2025 | Easyfuse, Augment Injectable |
| Paragon 28, INC. | $135.24 | 2022-2024 | Gorilla |
| Aroa Biosurgery Incorporated | $107.47 | 2022-2024 | |
| Paratek Pharmaceuticals, INC. | $75.35 | 2020-2025 | Nuzyra |
| Depuy Synthes Sales INC. | $69.80 | 2019-2022 | |
| Kci USA, INC. | $65.08 | 2019-2021 | |
| Organogenesis INC. | $61.62 | 2021-2023 | Puraply |
| Alfasigma USA, INC. | $61.13 | 2021-2022 | |
| Ibsa Pharma INC. | $56.40 | 2022-2024 | Tirosint, Licart, Licart |
| Abbvie INC. | $50.46 | 2021-2023 | |
| Wound Management Technologies, INC | $47.99 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $42.01 | 2021 | |
| Assertio Therapeutics, INC. | $40.17 | 2020 | |
| Solventum Corporation | $38.09 | 2024 | Prevena, V.A.C. Veraflo Cleanse Choice |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $36.73 | 2023 | Senza |
| Treace Medical Concepts, INC. | $36.33 | 2024 | |
| Boston Scientific Corporation | $33.52 | 2019 | |
| Bone Support INC. | $31.77 | 2024 | Ceramentbone Void Filler, Cerament G |
| Cardiovascular Systems INC. | $28.50 | 2019 | |
| Merck Sharp & Dohme LLC | $28.33 | 2019 | |
| Horizon Therapeutics Plc | $27.00 | 2019 | |
| Misonix INC | $25.11 | 2020 | |
| Globus Medical, INC. | $24.42 | 2025 | Senza |
| Biotissue Holdings INC. | $21.54 | 2025 | |
| Dynavax Technologies Corporation | $19.89 | 2025 | Heplisav-B |
| Pacira Pharmaceuticals Incorporated | $18.19 | 2021 | |
| Kerecis Limited | $18.01 | 2022 | |
| Acera Surgical, INC. | $17.66 | 2024 | Restrata Wound Matrix |
| Gilead Sciences, INC. | $17.41 | 2025 | |
| Medartis INC. | $15.91 | 2019 | |
| Melinta Therapeutics, LLC | $15.29 | 2019 | |
| Molnlycke Health Care US, LLC | $14.74 | 2025 | Exufiber, Mepilex, Setopress |
| Mimedx Group, INC. | $14.52 | 2025 | |
| Convatec INC. | $13.44 | 2021 | |
| Bioventus LLC | $13.43 | 2024 | Exogen Ultrasound Bone Healing System |
| Grt US Holding, INC. | $12.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Enzweiler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.